Global Non-oncology Biopharmaceuticals Market Growth (Status and Outlook) 2019-2024

SKU ID : LPI- 13598183

Publishing Date : 13-May-2019

No. of pages : 157

PRICE
3660
7320


  • Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. This report studies Non-oncology biopharmaceutical which are the drugs that are used in the treatment of various diseases rather than cancer.

    According to this study, over the next five years the Non-oncology Biopharmaceuticals market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Non-oncology Biopharmaceuticals business, shared in Chapter 3.

    This report presents a comprehensive overview, market shares and growth opportunities of Non-oncology Biopharmaceuticals market by product type, application, key companies and key regions.

    This study considers the Non-oncology Biopharmaceuticals value generated from the sales of the following segments:

    Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
    Biologics
    Biosimilars
    Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
    Immunology
    Endocrinology
    Others

    This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
    Americas
    United States
    Canada
    Mexico
    Brazil
    APAC
    China
    Japan
    Korea
    Southeast Asia
    India
    Australia
    Europe
    Germany
    France
    UK
    Italy
    Russia
    Spain
    Middle East & Africa
    Egypt
    South Africa
    Israel
    Turkey
    GCC Countries

    The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
    Roche
    Sanofi
    Johnson & Johnson
    Pfizer
    Novo Nordisk
    Novartis
    Merck
    Teva
    Eli Lilly
    Bristol-Myers Squibb
    GlaxoSmithKline
    UCB Pharma
    Amgen
    AbbVie
    Takeda
    AstraZeneca
    Mylan
    LEO Pharma
    Boehringer Ingelheim
    Alexion Pharmaceuticals
    Elusys Therapeutics
    Swedish Orphan Biovitrum
    Biogen

    In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

    Research objectives
    To study and analyze the global Non-oncology Biopharmaceuticals market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
    To understand the structure of Non-oncology Biopharmaceuticals market by identifying its various subsegments.
    Focuses on the key global Non-oncology Biopharmaceuticals players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
    To analyze the Non-oncology Biopharmaceuticals with respect to individual growth trends, future prospects, and their contribution to the total market.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    To project the size of Non-oncology Biopharmaceuticals submarkets, with respect to key regions (along with their respective key countries).
    To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
    To strategically profile the key players and comprehensively analyze their growth strategies.